Skip to main content
. 2020 Dec 10;2(4):100129. doi: 10.1016/j.jtocrr.2020.100129

Table 2.

Clinical Response to Nivolumab

Response Total (n = 17)
n % (95% CI)
ORR 5 29.4 (10.3–56.0)
Complete response 0 0
Partial response 5 29.4
Stable disease 5 29.4
Controlled disease 10 58.8 (32.9–81.6)
Progressive disease 5 29.4
Not assessable 2 11.8
 Duration of response (mo), median 6.5 (3.68–8.84)

CI, confidence interval; ORR, objective response rate.